Analysts think CASI stock price could increase by 105%
May 04, 2025, 11:26 AM
-5.03%
What does CASI do
CASI Pharmaceuticals, headquartered in Beijing, focuses on developing therapeutics, including the FDA-approved EVOMELA for multiple myeloma, and has a diverse pipeline targeting hematology oncology. The company went public on August 23, 2021, and employs 176 staff.
3 analysts think CASI stock price will increase by 105.03%. The current median analyst target is $4.08 compared to a current stock price of $1.99. The lowest analysts target is $4.04 and the highest analyst target is $4.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.